1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
3. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 2017; 377: 849–861.
4. Ohyama K, Yoshimi H, Aibara N, et al. Immune complexome analysis reveals the specific and frequent presence of immune complex antigens in lung cancer patients: A pilot study. Int J Cancer 2017;140:370-80.
5. Ladbury CJ, Rusthoven CG, Camidge DR, et al. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 2019;105:346-55.
6. Mendes F, Antunes C, Abrantes AM, et al. Lung cancer: the immune system and radiation. Br J Biomed Sci 2015;72:78-84.
7. Tian H, Chen Y, Zhao J, et al. Effects of siRNAs targeting CD97 immune epitopes on biological behavior in breast cancer cell line MDA-MB231. Zhejiang Da Xue Xue Bao Yi Xue Ban 2017;46:341-8.
8. Giatromanolaki A, Koukourakis IM, Balaska K, et al. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. Med Oncol 2019;36:76.
9. Zhang Y, Chen B, Wang L, et al. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis. Medicine (Baltimore) 2019;98:e13788.
10. Sun L, Zhang Z, Yao Y, et al. Analysis of expression differences of immune genes in non-small cell lung cancer based on TCGA and ImmPort data sets and the application of a prognostic model. Ann Transl Med 2020;8(8):550.
11. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997 ;89(17):1260-70.
12. Wang T, Liu H, Pei L, et al. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer. Clin Immunol 2020 ;210:108262.
13. Klupp F, Neumann L, Kahlert C, et al. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer 2016 ;16:494.
14. Su L, Zhou W, Asomaning K, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 2006 ;27(5):1024-9.
15. Bradbury PA, Zhai R, Hopkins J, et al. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis 2009 ;30(5):793-8.
16. Sarkar S, Nuttall RK, Liu S, et al. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 2006;66(24):11771-80.
17. Lv FZ, Wang JL, Wu Y, et al. Knockdown of MMP12 inhibits the growth and invasion of lung adenocarcinoma cells. Int J Immunopathol Pharmacol 2015 ;28(1):77-84.
18. Kowalczuk O, Burzykowski T, Niklinska WE, et al. CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumor Biol 2014;35(5):4619–4628.
19. Zhang J, Zhang J, Yuan C, et al. Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis. Cancer Cell Int 2020;20:330.
20. Kim JK, Jung KH, Noh JH, et al. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol 2009;35:1257–64.
21. Gibadulinova A, Pastorek M, Filipcik P, et al. Cancer-associated S100P protein binds and inactivatesp53, permits therapy-induced senescence and supports chemoresistance. Oncotarget 2016;7:22508–22.
22. Tan BS, Yang MC, Singh S, et al. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene. 2019 ;38(28):5612-5626.
23. Favorskaya I, Kainov Y, Chemeris G,et al. Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer. Tumour Biol 2014 ;35(10):10295-300.
24. Teng YC, Lee CF, Li YS, et al. Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res 2013 ;73(15):4711-21.
25. Wang S, Wang Y, Wu H, et al. RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer. PLoS One 2013;8: e84735.
26. Bolas G, de Rezende FF, Lorente C, et al. Inhibitory effects of recombinant RTS-jerdostatin on integrin alpha1beta1 function during adhesion, migration and proliferation of rat aortic smooth muscle cells and angiogenesis. Toxicon 2014;79: 45–54.
27. Belaiba RS, Bonello S, Zahringer C, et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007;18: 4691–4697.
28. Jahangiri A, Aghi MK, Carbonell WS. beta1 integrin: Critical path to antiangiogenic therapy resistance and beyond. Cancer Res 2014;74: 3–7.
29. Qi L, Zhu F, Li SH, et al. Retinoblastoma binding protein 2 (RBP2) promotes HIF-1α-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway. PLoS One 2014;9(8):e106032.
30. Xia J, Zhao J, Shang J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2015;308(7):L619-27.
31. Koca SS, Kara M, Deniz F, et al. Serum IL-33 level and IL-33 gene polymorphisms in Behçet's disease. Rheumatol Int 2015 ;35(3):471-7.
32. Mei L, Huang C, Wang A, et al. Association between ADRB2, IL33, and IL2RB gene polymorphisms and lung cancer risk in a Chinese Han population. Int Immunopharmacol 2019;77:105930.
33. Wang J, Liu Q, Yuan S, et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci Rep 2017 ;7(1):8371.
34. Li R, Liu X, Zhou XJ, et al. Identification and validation of the prognostic value of immune-related genes in non-small cell lung cancer. Am J Transl Res 2020 ;12(9):5844-5865.
35. Bertrand S, Brunet FG, Escriva H, et al. Evolutionary genomics of nuclear receptors: from twenty-five ancestral genes to derived endocrine systems. Mol Biol Evol 2004; 21:1923–37.
36. Wang J, Zhang J, Xu L, et al. Expression of HNF4G and its potential functions in lung cancer. Oncotarget 2017;9(26):18018-18028.
37. Bhattacharya S, Andorf S, Gomes L, et al. Imm Port: disseminating data to the public for the future of immunology. Immunol Res 2014; 58(2-3):234-239.
38. Sun L, Zhang Z, Yao Y, et al. Analysis of expression differences of immune genes in non-small cell lung cancer based on TCGA and ImmPort data sets and the application of a prognostic model. Ann Transl Med 2020 ;8(8):550.